PubMed:23554651 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23554651_2_0","span":{"begin":134,"end":148},"obj":"expanded"},{"id":"SS2_23554651_2_0","span":{"begin":150,"end":156},"obj":"abbr"},{"id":"SS1_23554651_5_0","span":{"begin":473,"end":484},"obj":"expanded"},{"id":"SS2_23554651_5_0","span":{"begin":486,"end":489},"obj":"abbr"},{"id":"SS1_23554651_5_1","span":{"begin":500,"end":520},"obj":"expanded"},{"id":"SS2_23554651_5_1","span":{"begin":522,"end":525},"obj":"abbr"}],"relations":[{"id":"AE1_23554651_2_0","pred":"abbreviatedTo","subj":"SS1_23554651_2_0","obj":"SS2_23554651_2_0"},{"id":"AE1_23554651_5_0","pred":"abbreviatedTo","subj":"SS1_23554651_5_0","obj":"SS2_23554651_5_0"},{"id":"AE1_23554651_5_1","pred":"abbreviatedTo","subj":"SS1_23554651_5_1","obj":"SS2_23554651_5_1"}],"text":"Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.\nOBJECTIVE: The association between ribonuclease L (RNASEL) gene polymorphisms and prostate cancer risk has been widely reported, but the results of these studies remained controversial and underpowered. We performed a meta-analysis of 28 studies to evaluate the association between Arg462Gln and Asp541Glu polymorphisms in the RNASEL gene and prostate cancer risk.\nMETHODS: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between RNASEL polymorphisms and prostate cancer risk.\nRESULTS: A significantly increased prostate cancer risk was found for the Arg462Gln polymorphism in Africans (Gln/Gln vs Arg/Arg: OR = 2.50, 95%CI = 1.28-4.87; Gln/Gln vs Gln/Arg + Arg/Arg: OR = 2.54, 95%CI = 1.30-4.95), but not in Europeans and Asians. Additionally, the Asp541Glu polymorphism was associated with increased total prostate cancer risk (Glu-allele vs Asp-allele: OR = 1.04, 95%CI = 1.01-1.07; Glu/Glu vs Asp/Asp: OR = 1.22, 95%CI = 1.03-1.46; Glu/Glu vs Glu/Asp + Asp/Asp: OR = 1.09, 95%CI = 1.02-1.16). In the stratified analysis for the Asp541Glu polymorphism, there was a significantly increased prostate cancer risk in Africans and Europeans, and in hospital-based prostate cancer cases.\nCONCLUSION: The meta-analysis results showed evidence that RNASEL Arg462Gln and Asp541Glu polymorphisms are associated with prostate cancer risk and could be low-penetrance prostate cancer susceptibility biomarkers."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":181,"end":196},"obj":"HP_0012125"},{"id":"T2","span":{"begin":190,"end":196},"obj":"HP_0002664"},{"id":"T3","span":{"begin":442,"end":457},"obj":"HP_0012125"},{"id":"T4","span":{"begin":451,"end":457},"obj":"HP_0002664"}],"text":"Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.\nOBJECTIVE: The association between ribonuclease L (RNASEL) gene polymorphisms and prostate cancer risk has been widely reported, but the results of these studies remained controversial and underpowered. We performed a meta-analysis of 28 studies to evaluate the association between Arg462Gln and Asp541Glu polymorphisms in the RNASEL gene and prostate cancer risk.\nMETHODS: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between RNASEL polymorphisms and prostate cancer risk.\nRESULTS: A significantly increased prostate cancer risk was found for the Arg462Gln polymorphism in Africans (Gln/Gln vs Arg/Arg: OR = 2.50, 95%CI = 1.28-4.87; Gln/Gln vs Gln/Arg + Arg/Arg: OR = 2.54, 95%CI = 1.30-4.95), but not in Europeans and Asians. Additionally, the Asp541Glu polymorphism was associated with increased total prostate cancer risk (Glu-allele vs Asp-allele: OR = 1.04, 95%CI = 1.01-1.07; Glu/Glu vs Asp/Asp: OR = 1.22, 95%CI = 1.03-1.46; Glu/Glu vs Glu/Asp + Asp/Asp: OR = 1.09, 95%CI = 1.02-1.16). In the stratified analysis for the Asp541Glu polymorphism, there was a significantly increased prostate cancer risk in Africans and Europeans, and in hospital-based prostate cancer cases.\nCONCLUSION: The meta-analysis results showed evidence that RNASEL Arg462Gln and Asp541Glu polymorphisms are associated with prostate cancer risk and could be low-penetrance prostate cancer susceptibility biomarkers."}